US company develops nanoemulsions to improve solubility


Therapeutics Solutions International, Inc., has announced successful production of a stable nanoemulsion of pterostilbene from ingredients Generally Regarded as Safe (GRAS). The nanoemulsion, which is a form of pterostilbene containing nanoparticles, is covered for use in cancer immunotherapy under the Company's issued U.S. Patent No.: 9,682,047. Pterostilbene is the active ingredient in the Company's patented


You need to be a subscriber to Nanotech Magazine to view this page. If you are a member please log-in, if you are not and wish to view this content please go to